EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA,…
Stayble Therapeutics AB ("Stayble" or "the Company") today provides an update on the ongoing work to establish partnerships for the…
EJ FÖRPUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA…
Stayble Therapeutics AB ("Stayble" or "the Company") has interviewed Rachelle, a US Payer Expert about her view on the US…
Stayble Therapeutics AB ("Stayble" or "the Company") has interviewed Jane Buus Laursen about her view from an experienced dealmakers perspective…
Stayble Therapeutics AB ("Stayble" or "the Company") CEO, Andreas Gerward, presented (in Swedish) the Company, the results from phase 1b,…
Stayble Therapeutics AB ("Stayble" or the "Company") has previously announced positive results from the Companys clinical phase 1b study in…
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the third quarter of 2024. The report…
Stayble Therapeutics AB ("Stayble" or the "Company") announces positive results from the Companys clinical phase 1b study in lumbar disc…
Stayble Therapeutics AB (“Stayble” or “the Company”) announced today that the European Patent Office (EPO) has issued an "Intention to…
Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the last patient visit has been completed in the phase…
Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the South African patent office, as the first country, has…
Stayble Therapeutics AB announces that Erik Kullgren has been appointed as the new CFO, effective August 1, 2024.
Erik Kullgren has…
Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Companys phase Ib study has reached the follow-up goal…
EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA,…
EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA,…
Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the first quarter of 2024. The report…
Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2023. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad…
Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 15 maj 2024 kl. 13.00 på bolagets kontor på…
Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Companys scientific abstract regarding the treatment concept for herniated discs…
Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been included in the ongoing phase…